

Viswanath Devanarayan

List of Publications by Citations

Source: <https://exaly.com/author-pdf/12093592/viswanath-devanarayan-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

3,869
citations

23
h-index

40
g-index

40
ext. papers

4,474
ext. citations

5.9
avg, IF

4.21
L-index

#	Paper	IF	Citations
35	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. <i>Nature Biotechnology</i> , 2010 , 28, 827-38	44.5	644
34	Fit-for-purpose method development and validation for successful biomarker measurement. <i>Pharmaceutical Research</i> , 2006 , 23, 312-28	4.5	572
33	Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. <i>Journal of Immunological Methods</i> , 2004 , 289, 1-16	2.5	509
32	Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008 , 48, 1267-81	3.5	434
31	The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance. <i>Nature Biotechnology</i> , 2014 , 32, 926-32	44.5	323
30	Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. <i>Journal of Immunological Methods</i> , 2008 , 333, 1-9	2.5	274
29	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. <i>Genome Biology</i> , 2015 , 16, 133	18.3	212
28	Confirmatory reanalysis of incurred bioanalytical samples. <i>AAPS Journal</i> , 2007 , 9, E336-43	3.7	119
27	Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005 , 36, 1037-44	3.5	109
26	Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 55, 878-88	3.5	93
25	Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development. <i>AAPS Journal</i> , 2016 , 18, 1-14	3.7	57
24	Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge. <i>Alzheimer's and Dementia</i> , 2016 , 12, 1014-1021	1.2	54
23	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity). <i>Bioanalysis</i> , 2015 , 7, 3107-24	2.1	51
22	Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013 , 27, 233-43	2.5	48
21	Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> , 2011 , 25, 73-84	2.5	45
20	Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points. <i>AAPS Journal</i> , 2017 , 19, 1487-1498	3.7	37
19	Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 433-41	2.2	36

18	Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011 , 1, 31-42	2.5	32
17	Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. <i>Bioanalysis</i> , 2015 , 7, 229-42	2.1	31
16	A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. <i>PLoS ONE</i> , 2017 , 12, e0182098	3.7	30
15	A PRIM approach to predictive-signature development for patient stratification. <i>Statistics in Medicine</i> , 2015 , 34, 317-42	2.3	29
14	Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls. <i>Alzheimer Disease and Associated Disorders</i> , 2012 , 26, 322-8	2.5	27
13	Patient subgroup identification for clinical drug development. <i>Statistics in Medicine</i> , 2017 , 36, 1414-1428	2.3	26
12	Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2006 , 41, 189-95	3.5	14
11	VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD. <i>Alzheimer Disease and Associated Disorders</i> , 2019 , 33, 307-314	2.5	12
10	Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib. <i>Lung Cancer</i> , 2015 , 90, 296-301	5.9	10
9	Report on the AAPS Immunogenicity Guidance Forum. <i>AAPS Journal</i> , 2019 , 21, 55	3.7	7
8	Cut Points and Performance Characteristics for Anti-Drug Antibody Assays 2011 , 287-308		7
7	Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. <i>AAPS Journal</i> , 2019 , 22, 7	3.7	6
6	Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework. <i>Journal of Alzheimer's Disease</i> , 2019 , 68, 537-550	4.3	5
5	Hearing Loss in Alzheimer's Disease Is Associated with Altered Serum Lipidomic Biomarker Profiles. <i>Cells</i> , 2020 , 9,	7.9	3
4	Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?. <i>AAPS Journal</i> , 2020 , 22, 127	3.7	2
3	Statistical Considerations in the Validation of Ligand-Binding Assays 111-128		1
2	Development and Validation of Immunogenicity Assays for Preclinical and Clinical Studies 193-238		1
1	Serum Phosphatidylethanolamine and Lysophosphatidylethanolamine Levels Differentiate Alzheimer's Disease from Controls and Predict Progression from Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021 , 80, 311-319	4.3	0

